Peer-influenced content. Sources you trust. No registration required. This is HCN.

Oncology Learning NetworkAnti–PD-L1 Therapy Not Recommended for Patients w. NSCLC, Active Brain Metastases

Dr. David P. Carbone, Director of the Thoracic Oncology Center at Ohio State University, comments on a study evaluating the efficacy of anti–PD1/PD-L1 monotherapy for patients with NSCLC and active brain metastases: “…the initial hope that PD‑1 inhibitors could be active on brain metastases has not been fully fulfilled, and the aggressive use of stereotactic radiation in that setting is useful.”

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form